Literature DB >> 15384881

Reduced gains in fat and fat-free mass, and elevated leptin levels in children and adolescents with cystic fibrosis.

M L Ahme1, K K Ong, A H Thomson, D B Dunger.   

Abstract

AIM: Bodyweight is an important prognostic indicator in children with cystic fibrosis (CF), but the relationships between body composition and clinical outcomes are less clear. We have investigated the role of leptin (a potential satiety factor) and changes in body composition, height and weight with respect to age and clinical outcome.
METHODS: 143 children (77 boys) with CF and a median age (range) of 5.99 (2.27-17.98) y were followed with annual measurements of height, weight, skinfolds, forced expiratory volume (FEV1), Shwachman score assessment and fasting blood sample. Our control group comprised 40 children (20 boys, 20 girls) aged 8.6-10.2 y at recruitment who were participating in a longitudinal study of growth and puberty.
RESULTS: SD scores for height, weight and BMI decreased with age; fat and fat-free mass was lower in both sexes compared to controls. Shwachman score decreased with age in both sexes and was related to fat-free mass in girls, and to both fat-free and fat mass in boys. FEV1 decreased with age only in boys and was related to fat-free mass. Leptin levels by age and by fat mass were higher in CF children compared to controls.
CONCLUSION: Despite improvements in management, contemporary children with CF still gain less body fat and fat-free mass and are shorter than controls. The higher leptin levels we observed may be due to stimulatory effects of inflammatory cytokines and we postulate that they may contribute to the anorexia, poor weight gain and growth of these children.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15384881

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  8 in total

1.  Absence of leptin signaling allows fat accretion in cystic fibrosis mice.

Authors:  Ilya R Bederman; Gavriella Pora; Maureen O'Reilly; James Poleman; Kimberly Spoonhower; Michelle Puchowicz; Aura Perez; Bernadette O Erokwu; Alex Rodriguez-Palacios; Chris A Flask; Mitchell L Drumm
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-08-17       Impact factor: 4.052

2.  Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D.

Authors:  Jordana E Hoppe; Brandie D Wagner; J Kirk Harris; Steven M Rowe; Sonya L Heltshe; Emily M DeBoer; Scott D Sagel
Journal:  J Cyst Fibros       Date:  2022-04-16       Impact factor: 5.527

3.  Circulating brain-derived neurotrophic factor, leptin, neuropeptide Y, and their clinical correlates in cystic fibrosis: a cross-sectional study.

Authors:  Jan K Nowak; Mariusz Szczepanik; Magdalena Trypuć; Andrzej Pogorzelski; Waldemar Bobkowski; Marcin Grytczuk; Alina Minarowska; Rafał Wójciak; Jaroslaw Walkowiak
Journal:  Arch Med Sci       Date:  2018-04-23       Impact factor: 3.318

4.  Dietary essential amino acids are highly anabolic in pediatric patients with cystic fibrosis.

Authors:  Mariëlle P K J Engelen; Gulnur Com; Robert R Wolfe; Nicolaas E P Deutz
Journal:  J Cyst Fibros       Date:  2013-01-26       Impact factor: 5.482

Review 5.  Leptin and its emerging role in children and adolescents.

Authors:  Iosif Kelesidis; Christos S Mantzoros
Journal:  Clin Pediatr Endocrinol       Date:  2006-02-22

6.  Serum leptin and neuropeptide Y in patients with cystic fibrosis-A single center study.

Authors:  Sabina Galiniak; Rafał Podgórski; Marta Rachel; Artur Mazur
Journal:  Front Med (Lausanne)       Date:  2022-09-14

7.  The association between body composition, leptin levels and glucose dysregulation in youth with cystic fibrosis.

Authors:  Andrea Granados; Elizabeth A Beach; Andrew J Christiansen; Bruce W Patterson; Michael Wallendorf; Ana María Arbeláez
Journal:  J Cyst Fibros       Date:  2021-06-26       Impact factor: 5.527

8.  Variation in plasma leptin levels in young Iranian children with cystic fibrosis.

Authors:  Maryam Monajemzadeh; Mohammad Taghi Haghi Ashtiani; Ehsan Sadrian; Sedigheh Shams; Farzaneh Motamed; Mehri Najafi Sani; Setareh Sadat Banihosseini; Ata Abbasi
Journal:  Arch Med Sci       Date:  2013-11-05       Impact factor: 3.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.